R. Matsumura et al. / Tetrahedron Letters 42 (2001) 1543–1546
1545
BnO
OMs
BnO
OH
H
H
H
H
OTHP
OH
O
O
e,f,g
a,b
H
c,d
2
11
12
BnO
OAc
BnO
OH
H
H
H
OH
O
O
O
h,i,j,k
l
13
14
BnO
Cl
Br
Cl
H
H
H
H
O
13
m,n
6
15
(+)-rogioloxepane A (1)
Scheme 4. Reagents and conditions: (a) MsCl, TEA, DMAP, CH2Cl2, 100%; (b) PhSH, ZnCl2, CH2Cl2, 0°C, 93%; (c) K2CO3,
MeOH–CH2Cl2 (1:1), 98%; (d) HCꢀCCH2OTHP, n-BuLi, BF3·OEt2, −78°C, 99%; (e) H2, Lindlar cat., quinoline, AcOEt, 100%;
(f) Ac2O, TEA, DMAP, CH2Cl2, 97%; (g) PPTS, EtOH, 50°C, 98%; (h) MnO2, CHCl3–benzene (1:2); (i) CBr4, HMPT, THF, 0°C;
(j) K2CO3, MeOH; (k) n-BuLi, THF, −90 to −40°C, 56% (four steps), cis:trans=20:1; (l) CCl4, (Oct)3P, 1-methyl-1-cyclohexene,
toluene, 80°C, 49%; (m) DDQ, CH2ClCH2Cl–H2O (9:1), 50°C, 100%; (n) CBr4, (Oct)3P, 1-methyl-1-cyclohexene, toluene, 70°C,
70%.
Acknowledgements
the reaction was completed in 1 minute without isomer-
ization of the double bond in conjugation to the alde-
hyde group. Deprotection of the acetyl group followed
by treatment with n-BuLi furnished the cis-enyne 14 in
56% yield over four steps as a 20:1 mixture of Z:E
stereoisomers. The cis-enyne 14 was purified by MPLC
at this stage and subjected to further manipulations.
This work was financially supported in part by the
Grant-in-Aid for Scientific Research on Priority Area
No. 08245101 from the Ministry of Education, Science,
Sports and Culture, of Japanese Government.
Several attempts to introduce the chlorine functionality
at C6 with inversion of configuration were unsuccessful
due to the competitive elimination. The best method
finally founded for this transformation was CCl4 and
(Oct)3P in toluene in the presence of 1-methyl-1-cyclo-
hexene to afford chloride 15 in 49% yield along with the
elimination product (24%). In the absence of 1-methyl-
1-cyclohexene, a trace amount of by-products halo-
genated on the double bond(s) were formed, separation
of which from the desired product was troublesome.
DDQ was employed for cleavage of the benzyl ether of
15 according to our earlier observation (vide supra).
Finally, the resulting hydroxy group at C13 was bromi-
nated by the procedure of Murai12 with addition of
1-methyl-1-cyclohexene to furnish (+)-1 in 70% yield
with complete inversion of configuration. The synthetic
material was identical in all respects (1H NMR, 13C
NMR, [h]D, and MS)3 to those reported for natural
(+)-1.
References
1. (a) Moore, R. E. In Marine Natural Products; Scheuer, P.
J., Ed.; Academic Press: New York, 1978; Vol. 1, pp.
43–221; (b) Erickson, K. L. In Marine Natural Products;
Scheuer, P. J., Ed.; Academic Press: New York, 1983;
Vol. 5, pp. 131–257.
2. For reviews of synthetic investigations in this area, see:
(a) Albizati, K.; Martin, V. A.; Agharahimi, M. R.;
Stolze, D. A. In Bioorganic Marine Chemistry; Scheuer,
P. J., Ed.; Springer-Verlag: Berlin, 1992; Vol. 6, pp.
69–84; (b) Elliott, M. C. Contemp. Org. Synth. 1994,
457–474.
3. Guella, G.; Mancini, I.; Chasera, G.; Pietra, F. Helv.
Chim. Acta 1992, 75, 310–322.
4. (a) Carling, R. W.; Clark, J. S.; Holmes, A. B. J. Chem.
Soc., Perkin Trans. 1 1992, 83–94; (b) Feng, F.; Murai, A.
Chem. Lett. 1992, 1587–1590; (c) Davies, M. J.; Moody,
C. J. J. Chem. Soc., Perkin Trans. 1 1991, 9–12; (d)
Yamada, J.; Asano., T.; Kadota., I.; Yamamoto, Y. J.
Org. Chem. 1990, 50, 6066–6068; (e) Kotsuki, H.; Ushio,
Y.; Kadota, I.; Ochi, M. J. Org. Chem. 1989, 54, 5153–
5161; (f) Castan˜eda, A.; Kucera, D. J.; Overman, L. E. J.
Org. Chem. 1989, 54, 5698–5707.
5. (a) Mujica, M. T.; Afonso, M. M.; Galindo, A.; Palen-
zuela, J. A. Tetrahedron Lett. 1994, 35, 3401–3404; (b)
Davies, M. J.; Moody, C. J.; Taylor, R. J. Synlett 1990,
93–96.
In conclusion, the first total synthesis of (+)-rogiolox-
epane A (1) was accomplished with high stereoselectiv-
ity. This synthesis has established that the cyclization of
hydroxy epoxides promoted by the (Bu3Sn)2O/Zn(OTf)2
system is an efficient methodology for the synthesis of
highly functionalized seven-membered oxacyclics. In
addition, the proposed 6R and 13R configurations3
were synthetically confirmed.